Board

Hans Wigzell
Chairman and Board member since 2006.
Born 1938. MD and Professor of Immunology.

Other appointments
Chariman of Rhenman & Partner Asset Management AB. Board member of AviBiopharma Inc., Swedish Orphan Biovitrum AB,  Humalabs LLC, Intercell AG and RaySearch Laboratories AB. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of the Smittskyddsinstitutet.

Holdings in Karolinska Development: 8 491 shares.

Rune Fransson
Board member since 2006.
Born 1947. BSc. in Economics.

Other appointments
Chairman of Karolinska Institutet Holding AB and the University Accommodation Center AB. Previous assignments include, among others, Board member of KI Health Management.

Holdings in Karolinska Development: 0 shares.

Ulrica Slåne
Board member since 2007.
Born 1965 MSc. in Business and Economics and CFA. Studies in physiology and pharmacology at the Karolinska Institutet.

Other appointments
Board Member of Diagenic ASA. Portfolio Manager at the Third AP Fund. Board memeber of Diagenic ASA, Oslo. Ulrica has more than 20 years experience as an analyst and fund manager in the life science sector.

Holdings in Karolinska Development: 0 shares.

Peter Sjöstrand
Board member since 2008.
Born 1946. MD and MSc. in Business and Economics.

Other appointments
Chairman of Life Science Imaging, Stiftelsen Oscar Hirschs Minne, Byggnads AB S:t Erik and Life Science Imaging. Board member of Active Biotech AB and Calmark AB. Member of Vatera Holding Advisory Board and Senior Industrial Advisor EQT. Previous assignments include, among others, AGA, Aleris, Astra (alternate), Astra-Merck, Gambro, Meda, Medivir, Mediject, Pharma Vision, Symbicom, Trygg Hansa and Tularik.

Holdings in Karolinska Development: 0 shares.

Per-Olof Edin
Board member since 2007.
Born 1940. Professor.

Other appointments
Vice Chairman of the Seventh AP Fund. Previous assignments include, among others, Chairman of Södertörn University College and the Baltic Sea Foundation.

Holdings in Karolinska Development: 0 shares.

Michael Rosenlew
Board member since 2010.
Born 1959. MSc. (Econ.) in Corporate Finance and Accounting

Other appointments
Including, Chairman of Mikaros AB and Time System Finland Oy. Board member of Mikaros Invest AB, Alfa AB, YIT Oyj, TimeSystem Holding AG, Oy Desinfinator Ltd, Mikaros Fastigheter AB and Oy Hold 1 Ltd. Previous assignments include Managing Partner and member of the Executive Committee of IK Investment Partners. Prior to IK he held both financial and managerial positions in a number of Finnish companies including the Amer Group.

Holdings in Karolinska Development: 75 000 shares.

Raymond Hill
Board member since 2011.
Born 1945. PhD. DSc. (Hon), FMedSci

Other appointments
Visiting Professor at Bristol, Surrey, Imperial and Strathclyde Universities. He is President Emeritus of the British Pharmacological Society and a Member of Council of the Academy of Medical Sciences. In 2011 he received the Sir James Black Award for Drug Discovery from the BPS in recognition of his part in the introduction of Maxalt and Emend during the time he worked for Merck / MSD. He is a non-Executive Director of the Swiss companies Addex and Covagen and of Orexo in Sweden

Holdings in Karolinska Development: 0 shares.